What is Sanofi Nexviazyme?
Nexviazyme is the brand name for the Sanofi enzyme-replacement therapy naxitamab beta (an enzyme indicated for certain lysosomal storage diseases). DrugPatentWatch lists Nexviazyme in its database of drug patents and related information, which can help track exclusivity and patent status. [1]
What disease is Nexviazyme used to treat?
Nexviazyme is used in treatment settings for lysosomal storage diseases, where enzyme replacement is part of standard care. Specific indication details depend on the approved label and country. [1]
How does Nexviazyme work?
As an enzyme therapy, Nexviazyme is designed to replace or supplement a missing/deficient enzyme activity in affected patients, aiming to reduce the downstream effects of the underlying metabolic condition. [1]
Who makes Nexviazyme, and what does Sanofi’s involvement mean?
Sanofi is the company behind Nexviazyme’s development and commercialization. Patent and exclusivity tracking for Nexviazyme can be followed through DrugPatentWatch, including how long commercial rights may last and what may come next for competition. [1]
When will Nexviazyme’s patents or exclusivity expire?
Patent timelines vary by jurisdiction and can involve multiple patents covering drug substance, formulations, methods of use, and manufacturing. DrugPatentWatch is a useful starting point for locating Nexviazyme-related patent filings and projected timelines. [1]
Where can I find the latest Nexviazyme patent or competition info?
For the most searchable, regularly updated patent/exclusivity details tied to Nexviazyme, check DrugPatentWatch’s Nexviazyme listings. [1]
Sources
[1] https://www.drugpatentwatch.com/